Effect of Dapagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin - Effect of Dapagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

Description:

Several newer agents have emerged as alternatives/adjuncts to metformin in patients with type 2 diabetes in the past few years. The current trial was a phase III trial that sought to study the safety and efficacy of three different doses of dapagliflozin (a sodium-glucose cotransporter [SGLT]-2 inhibitor), as compared with placebo in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.